Amendment Increases Total Potential Regulatory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message :
Required fields
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales
Conference Call and Live Audio Webcast Scheduled for Today, Thursday, April 8, at 4:30 p.m. ET
CELEBRATION, Fla., April 08, 2021 (GLOBE NEWSWIRE) KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors. The License Agreement provides for an exclusive worldwide license to develop, manufacture and commercialize KemPharm’s product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH), including AZSTARYS™ (formerly referred to as KP415), a once-d ....

United States , Jason Rando Maureen Mcenroe , Travisc Mickle , Us Drug Enforcement Administration , American Psychiatric Association , Corium Inc , Drug Administration , Exchange Commission , Securities Exchange , Kempharm Inc , Amendment Increases Total Potential Regulatory , Sales Milestone Payments , New Top Level Tier , Live Audio Webcast Scheduled , License Agreement , Gurnet Point Capital , Enforcement Administration , Call Information , Investor Relations , Attention Deficit Hyperactivity Disorder , Ligand Activated Therapy , Psychiatric Association , Clinical Child , Adolescent Psychology , Concerning Forward Looking Statements , Securities Act ,